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Quality Review of Irradiated Cellular Blood Product Orders
Matthew Grzywinski1, Vandi Ly, M.D.2
1: Sidney Kimmel Medical College, 2: Thomas Jefferson University Department of Pathology

Background

Interventions to Decrease Inappropriate Orders

Discussion

Transfusion-associated graft-versus-host disease (TA-GVHD) is an immunological
response between a donor’s transfused T cells and the recipient’s immune defense. The
risk of TA-GVHD increases with relatively large transfusions of lymphocytes (e.g.
transfusion in infants or granulocyte transfusion) or immunocompromised individuals.
The risk of TA-GVHD is mitigated by irradiating cellular blood components to prevent
donor T lymphocyte proliferation.

Two interventions were undertaken to decrease the number of inappropriate
irradiation orders.

Next Steps
• Dr. Julie Karp, Associate Director of the Thomas Jefferson University Blood Bank,
will give an educational lecture to the Department of Medicine residents on blood
products (including irradiated cellular blood products) on June 13, 2017
• Irradiated cellular blood product orders will be reviewed to determine if the number
of inappropriate orders decrease over time.

Irradiation of cellular blood components is managed differently amongst institutions.
Factors to consider in the irradiation process include technologist time. Technologists
prepare and perform irradiation of the cellular blood products. This can be a labor
intensive process. Cost is another factor that includes the cost of the irradiation
indicators that are placed on the units and the labor in providing this service.
Irradiation also shortens the shelf life of the cellular blood component to 28 days. If the
shelf life was less than 28 days then irradiation does not extend the shelf life to 28 days
(e.g. shelf life 14 days, post-irradiation remains 14 days). At Thomas Jefferson
University Hospital, the Blood Bank irradiates blood products only upon request, then
reviews the initial orders to determine if irradiation is indeed indicated. The decision
whether irradiation is appropriate is determined by having medical coverage review the
requests.

A polite and professional email was sent to the clinicians who submitted the
inappropriate irradiation orders from July 2016 to March 2017. The email informed the
clinician that they submitted an inappropriate irradiation order, provided them with a
table of irradiation blood product indications, and additional resources. This email was
sent on February 27, 2017.

Possible Further Interventions
• Email all Jefferson residents informing them of the indications for irradiated
cellular blood products.
• Email Jefferson faculty informing them of the indications for irradiated cellular
blood products.
• Present the findings of this research and the indications for irradiated cellular blood
products to Jefferson residents at seminars, conferences, or meetings.
Limitations
• Only the clinician who submitted the inappropriate irradiation order was contacted,
not the entire care team.
• The preliminary post-intervention data may not be representative since residents
gain experience during the year.
•

Only one year of inappropriate orders were reviewed.
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